Allogene Therapeutics ALLO Stock
Allogene Therapeutics Price Chart
Allogene Therapeutics ALLO Financial and Trading Overview
Allogene Therapeutics stock price | 1.44 USD |
Previous Close | 4.99 USD |
Open | 4.95 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 4000 |
Day's Range | 4.79 - 5.03 USD |
52 Week Range | 4.42 - 17.49 USD |
Volume | 2.67M USD |
Avg. Volume | 2.02M USD |
Market Cap | 724.83M USD |
Beta (5Y Monthly) | 0.767284 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.32 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.59 USD |
ALLO Valuation Measures
Enterprise Value | 355.5M USD |
Trailing P/E | N/A |
Forward P/E | -2.133047 |
PEG Ratio (5 yr expected) | -2.42 |
Price/Sales (ttm) | 3097.5842 |
Price/Book (mrq) | 1.2229329 |
Enterprise Value/Revenue | 1519.229 |
Enterprise Value/EBITDA | -1.044 |
Trading Information
Allogene Therapeutics Stock Price History
Beta (5Y Monthly) | 0.767284 |
52-Week Change | -54.65% |
S&P500 52-Week Change | 20.43% |
52 Week High | 17.49 USD |
52 Week Low | 4.42 USD |
50-Day Moving Average | 5.56 USD |
200-Day Moving Average | 7.84 USD |
ALLO Share Statistics
Avg. Volume (3 month) | 2.02M USD |
Avg. Daily Volume (10-Days) | 2.33M USD |
Shares Outstanding | 145.84M |
Float | 84.75M |
Short Ratio | 18.76 |
% Held by Insiders | 29.15% |
% Held by Institutions | 78.32% |
Shares Short | 40.03M |
Short % of Float | 43.58% |
Short % of Shares Outstanding | 27.45% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -151507.26% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -25.89% |
Return on Equity (ttm) | -48.56% |
Income Statement
Revenue (ttm) | 234K USD |
Revenue Per Share (ttm) | 0.002 USD |
Quarterly Revenue Growth (yoy) | -14.79% |
Gross Profit (ttm) | 243K USD |
EBITDA | -340416992 USD |
Net Income Avi to Common (ttm) | -351486016 USD |
Diluted EPS (ttm) | -2.12 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 471.22M USD |
Total Cash Per Share (mrq) | 3.23 USD |
Total Debt (mrq) | 99.7M USD |
Total Debt/Equity (mrq) | 16.83 USD |
Current Ratio (mrq) | 8.08 |
Book Value Per Share (mrq) | 4.064 |
Cash Flow Statement
Operating Cash Flow (ttm) | -218920992 USD |
Levered Free Cash Flow (ttm) | -101178376 USD |
Profile of Allogene Therapeutics
Country | United States |
State | CA |
City | South San Francisco |
Address | 210 East Grand Avenue |
ZIP | 94080 |
Phone | 650 457 2700 |
Website | https://www.allogene.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 359 |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Q&A For Allogene Therapeutics Stock
What is a current ALLO stock price?
Allogene Therapeutics ALLO stock price today per share is 1.44 USD.
How to purchase Allogene Therapeutics stock?
You can buy ALLO shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allogene Therapeutics?
The stock symbol or ticker of Allogene Therapeutics is ALLO.
Which industry does the Allogene Therapeutics company belong to?
The Allogene Therapeutics industry is Biotechnology.
How many shares does Allogene Therapeutics have in circulation?
The max supply of Allogene Therapeutics shares is 217.27M.
What is Allogene Therapeutics Price to Earnings Ratio (PE Ratio)?
Allogene Therapeutics PE Ratio is now.
What was Allogene Therapeutics earnings per share over the trailing 12 months (TTM)?
Allogene Therapeutics EPS is -1.32 USD over the trailing 12 months.
Which sector does the Allogene Therapeutics company belong to?
The Allogene Therapeutics sector is Healthcare.
Allogene Therapeutics ALLO included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 1938.96 USD — |
-4.51
|
— — | 1891.68 USD — | 1965.66 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}